The drug development process is costly, time consuming and laden with risk—with only 1% of drugs making it from pre-clinical all the way to market, according to Pharma Intelligence. To beat these odds, life sciences leaders must know when to continue funding a promising, new product and when to call it quits.

Tune in for insights into:

• Why a “fast to failure” mentality is key to a successful development pipeline
• How leaders can redivert organizational resources after ending a program
• Why drug development failures can ultimately lead to positive outcomes